Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

ABSTRACT:

Importance

Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti-programmed cell death 1 (PD-1) antibodies have antitumor activity in this disease, but little is known about the activity of anti-programmed cell death ligand 1 (PD-L1) antibodies in patients with mesothelioma.

Objective

To assess the efficacy and safety of avelumab in a cohort of patients with previously treated mesothelioma.

Design, setting, and participants

Phase 1b open-label study (JAVELIN Solid Tumor) in patients with unresectable mesothelioma that progressed after platinum and pemetrexed treatment, enrolled at 25 sites in 3 countries between September 9, 2014, and July 22, 2015.

Interventions

Participants receive

SUBMITTER: Hassan R 

PROVIDER: S-EPMC6439847 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature